Drug–drug interaction: CC-122 + fluvoxamine

The entry 'Drug–drug interaction: CC-122 + fluvoxamine' does not represent a single biological target molecule but rather a clinical pharmacological interaction between two distinct drugs. CC-122, also known as Avadomide, is a Cereblon E3 ligase modulator (CELMoD) that targets the CRBN protein to induce the degradation of lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), primarily for the treatment of B-cell malignancies (Hagner et al., 2015, Blood). Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a potent inhibitor of several cytochrome P450 enzymes, including CYP1A2 and CYP2C19 (PubChem, CID 5323057). This specific interaction has been the subject of clinical investigation (e.g., NCT02442011) to evaluate how fluvoxamine-mediated enzyme inhibition affects the pharmacokinetics and safety profile of CC-122 (ClinicalTrials.gov). Because CC-122 undergoes oxidative metabolism, co-administration with fluvoxamine can lead to increased drug exposure, which significantly elevates the risk of hematologic toxicities such as neutropenia. Consequently, this profile is used by biotech analysts and clinicians to establish safety margins and dosing guidelines rather than to define a therapeutic receptor.

Other names

CC-122 and Fluvoxamine interactionAvadomide-Fluvoxamine DDIPharmacokinetic interaction of CC-122 and Fluvoxamine

Fluvoxamine acts as a potent inhibitor of cytochrome P450 enzymes (specifically CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A4), which may reduce the metabolic clearance and increase the systemic exposure of CC-122.